iotacarrageenan
ic
activ
respiratori
virus
vitro
effect
nasal
spray
three
previou
clinic
trial
current
trial
serv
investig
ic
patient
earli
common
cold
symptom
method
random
placebocontrol
doubleblind
phase
iv
trial
conduct
adult
patient
selfdiagnos
cold
h
durat
confirm
baselin
cold
symptom
score
patient
selfadminist
ic
placebo
spray
nacl
four
time
daili
four
ten
day
record
symptom
inform
ten
day
common
respiratori
virus
quantifi
rtpcr
pretreat
day
primari
endpoint
mean
total
symptom
score
tss
eight
cold
symptom
day
tss
result
patient
treatment
group
similar
baselin
tsss
mean
tss
ic
placebo
virus
detect
baselin
sampl
ic
patient
placebo
patient
mean
se
tss
ic
patient
placebo
p
exploratori
analys
unblind
tss
exclud
patient
aberrantli
high
symptom
score
tss
ex
mean
tss
day
tss
chang
tss
rel
baselin
rel
demonstr
treatment
differ
favor
ic
p
p
p
respect
patient
quantifi
rhinovirusenteroviru
baselin
trend
toward
greater
reduct
viru
load
day
p
ic
reduct
viral
load
placebo
treatment
well
toler
differ
advers
event
rate
conclus
primari
endpoint
demonstr
statist
signific
differ
ic
placebo
show
trend
toward
ic
benefit
exploratori
analys
indic
signific
reduct
cold
symptom
ic
group
rel
placebo
first
four
day
symptom
sever
also
substanti
ic
activ
rhinovirusenteroviru
trial
registr
clinicaltrialsgov
common
cold
caus
varieti
respiratori
virus
human
rhinovirus
hrv
coronavirus
human
enterovirus
hev
respiratori
syncyti
viru
rsv
parainfluenza
virus
influenza
virus
rhinovirus
common
caus
respiratori
tract
infect
individu
age
adult
rhinovirus
caus
approxim
common
cold
cold
autumn
epidem
season
common
cold
frequent
ill
children
adult
averag
adult
report
episod
per
year
estim
total
econom
impact
noninfluenzarel
viral
upper
respiratori
tract
infect
approach
billion
annual
infect
result
seriou
even
lifethreaten
sequela
patient
underli
ill
asthma
copd
immun
compromis
except
influenza
rsv
vaccin
antivir
medicin
product
avail
treatment
infect
virus
caus
common
cold
iotacarrageenan
ic
sulfat
polysaccharid
found
speci
red
seawe
chondru
crispu
demonstr
antivir
activ
respiratori
virus
cell
cultur
anim
model
ic
polym
seem
bind
directli
virus
prevent
viral
attach
host
cell
vitro
vivo
studi
demonstr
effect
ic
sever
virus
hrv
influenza
vitro
test
establish
ic
penetr
freshli
excis
bovin
nasal
mucosa
therefor
absorb
system
data
file
marinom
biotechnolog
gmbh
carrageenan
gener
recogn
safe
gra
use
food
topic
applic
primari
site
infect
replic
coldcaus
virus
nasal
mucosa
specul
earli
target
treatment
nasal
mucosa
ic
may
block
viral
entri
level
respiratori
mucosa
interfer
local
propag
viral
replic
therefor
nasal
spray
contain
salin
iotacarrageenan
ic
nasal
spray
develop
regist
medic
devic
product
recent
licens
boehring
ingelheim
sponsor
current
studi
three
random
clinic
trial
two
adult
one
children
conduct
compar
ic
nasal
spray
salin
solut
placebo
trial
indic
efficaci
includ
significantli
reduc
cold
symptom
posit
effect
symptom
patient
less
comed
comed
use
significantli
reduc
viral
load
faster
reduct
common
cold
symptom
treatment
safe
well
toler
icicc
trial
icicc
iotacarrageenan
common
cold
design
control
evalu
safeti
efficaci
ic
treatment
patient
earli
common
cold
symptom
effect
treatment
cold
symptom
durat
cold
viral
load
assess
icicc
trial
conduct
common
cold
center
cardiff
wale
uk
random
placebocontrol
doubleblind
twoarm
parallel
group
trial
aim
investig
efficaci
ic
nasal
spray
comparison
placebo
nasal
spray
treatment
earli
common
cold
adult
year
trial
regist
clinicaltrialsgov
access
number
volunt
patient
recruit
poster
advertis
around
cardiff
univers
campu
email
student
staff
cardiff
univers
base
result
previou
trial
calcul
sampl
size
group
would
power
detect
expect
differ
mean
tss
score
group
see
definit
tss
therefor
plan
includ
total
patient
elig
random
elig
particip
patient
common
cold
symptom
h
trial
entri
base
selfreport
screen
interview
patient
rate
eight
common
cold
symptom
headach
muscl
ach
chilli
sore
throat
block
nose
runni
nose
cough
sneez
rate
scale
symptom
maximum
sever
total
symptom
score
sum
eight
common
cold
symptom
baselin
patient
also
score
least
one
follow
symptom
sore
throat
runni
nose
block
nose
reflect
standard
cold
studi
design
accord
jackson
inclus
criteria
construct
similarli
previou
clinic
trial
conduct
ic
patient
high
symptom
score
exclud
order
recruit
patient
earli
stage
cold
exclud
subject
later
infect
strategi
design
start
treatment
earli
optim
chanc
improv
clinic
cours
cold
earli
intervent
strategi
may
partial
respons
lower
power
studi
sinc
proport
patient
trial
develop
fullblown
cold
rel
high
reflect
rhinovirusposit
patient
see
result
discuss
patient
instruct
selfadminist
puff
ml
trial
medic
nostril
time
per
day
trial
medic
either
ic
nasal
spray
g
iotacarrageenanl
nacl
placebo
nacl
patient
investig
blind
treatment
alloc
treatment
mandatori
day
depend
patient
prefer
could
continu
addit
day
result
maximum
treatment
durat
day
patient
record
symptom
per
day
even
day
symptom
diari
use
rate
scale
eight
cold
symptom
see
primari
endpoint
trial
mean
total
symptom
score
tss
document
eight
singl
cold
symptom
calcul
averag
daili
sum
day
tss
secondari
endpoint
includ
mean
daili
sum
three
system
common
cold
symptom
headach
muscl
ach
chilli
day
sss
mean
daili
sum
singl
local
common
cold
symptom
sore
throat
block
nose
runni
nose
cough
sneez
day
lss
area
curv
auc
daili
symptom
score
period
auctss
calcul
sum
eight
singl
cold
symptom
day
durat
cold
determin
patient
answer
diari
question
still
cold
end
treatment
day
patient
assess
efficaci
evalu
end
trial
visit
patient
answer
question
effect
treatment
reliev
common
cold
symptom
use
scale
poor
fair
good
good
excel
prespecifi
endpoint
includ
tss
studi
day
day
viral
load
chang
baselin
day
variou
viru
type
trial
data
unblind
three
exploratori
analys
perform
assess
tss
exclud
patient
aberrantli
high
symptom
score
tss
ex
mean
tss
day
tss
chang
tss
rel
baselin
tss
rel
adjust
potenti
impact
baselin
tss
tss
tss
tss
score
rang
ic
group
placebo
group
calcul
tss
rel
tss
subtract
tss
result
divid
tss
addit
tss
score
calcul
viru
posit
subset
hrvhev
posit
subset
see
analysi
set
definit
safeti
assess
basi
incid
treatmentemerg
advers
event
ae
overal
toler
assess
patient
record
investig
final
visit
respiratori
virus
viral
load
determin
nasopharyng
lavag
sampl
obtain
baselin
either
day
viral
presenc
determin
patient
use
qualit
quantit
test
respiratori
virus
realtim
polymeras
chain
reaction
rtpcr
use
qualit
determin
presenc
influenza
b
picornavirus
hrvhev
human
bocaviru
human
metapneumoviru
coronavirus
adenoviru
human
parechoviru
respiratori
syncyti
viru
parainfluenza
viru
type
quantit
viral
load
hrv
hev
determin
use
assay
quantit
viral
load
influenza
b
coronavirus
assess
accord
garbino
et
al
panenterhinog
assay
provid
quantifi
hrv
hev
viral
load
result
howev
patient
viru
detect
viral
load
level
quantif
test
patient
consid
virusposit
nonquantifi
qualit
posit
result
total
number
virusposit
patient
obtain
sum
number
patient
posit
result
qualit
assay
detect
quantit
quantifi
nonquantifi
result
assay
two
main
analysi
set
treat
set
full
analysi
set
fa
evalu
treat
set
includ
patient
document
taken
least
one
dose
trial
medic
use
safeti
analys
fa
includ
patient
document
taken
least
one
dose
trial
medic
baselin
tss
record
suppli
data
assess
primari
endpoint
fa
use
analysi
primari
secondari
endpoint
three
analysi
subset
within
fa
also
defin
unblind
includ
viru
posit
subset
patient
whose
nasal
lavag
specimen
yield
least
one
posit
qualit
detect
quantit
quantifi
nonquantifi
result
baselin
hrvhev
posit
subset
patient
whose
lavag
yield
least
detect
quantifi
nonquantifi
result
assay
baselin
quantifi
hrvhev
subset
patient
quantifi
result
assay
baselin
subset
use
analysi
addit
exploratori
endpoint
primari
endpoint
tss
analyz
use
analysi
covari
ancova
adjust
continu
covari
tss
treatment
differ
ic
placebo
treatment
group
assess
base
adjust
mean
correspond
twosid
confid
interv
ci
secondari
endpoint
sss
lss
auctss
adjust
tss
treatment
analyz
similarli
three
exploratori
endpoint
tss
ex
tss
tss
rel
analyz
way
primari
endpoint
adjust
tss
treatment
endpoint
miss
singl
symptom
score
baselin
postbaselin
measur
time
replac
zero
least
one
eight
symptom
score
avail
thereaft
miss
daili
tss
lss
sss
data
replac
last
observ
carri
forward
procedur
durat
cold
examin
record
time
loss
cold
defin
first
respons
question
still
cold
patient
daili
symptom
diari
log
rank
test
stratifi
tss
use
compar
treatment
group
endpoint
variabl
censor
day
patient
recov
cold
test
whether
patient
assess
efficaci
differ
ic
group
placebo
group
ordin
logist
regress
model
adjust
tss
appli
efficaci
score
provid
patient
miss
entri
assign
least
favor
categori
analysi
endpoint
variabl
tss
studi
day
day
use
restrict
maximum
likelihoodbas
repeat
measur
approach
use
longitudin
tss
data
day
statist
model
includ
fix
categor
effect
treatment
day
treatmentbyday
interact
continu
covari
tss
unstructur
covari
structur
use
model
withinpati
error
miss
singl
symptom
score
baselin
postbaselin
measur
time
replac
least
one
symptom
score
avail
patient
miss
tss
specif
day
subsequ
day
day
cold
end
day
question
still
cold
answer
day
latest
miss
tss
valu
subsequ
day
day
replac
case
imput
miss
tss
valu
perform
mean
chang
viral
load
baselin
adjust
continu
covari
baselin
viral
load
treatment
use
ancova
differ
ic
placebo
treatment
assess
base
adjust
mean
correspond
ci
calcul
use
twosid
approach
quantit
viral
load
analys
miss
valu
valu
limit
quantif
loq
replac
loq
valu
approxim
patient
evalu
respect
symptomatolog
durat
symptom
prescreen
formal
enrol
screen
enrol
patient
one
random
random
treat
ic
n
placebo
n
overal
enter
patient
complet
trial
treatment
prematur
discontinu
treatment
trial
medic
proport
patient
discontinu
treatment
similar
treatment
group
ic
patient
placebo
patient
frequent
reason
trial
discontinu
lost
followup
ic
patient
placebo
patient
treat
patient
ic
group
placebo
group
provid
data
primari
endpoint
includ
fa
fig
includ
patient
treat
baselin
demograph
characterist
compar
ic
placebo
group
tabl
primari
endpoint
tss
lower
ic
group
ci
placebo
group
ci
differ
statist
signific
ci
pvalu
tabl
secondari
endpoint
sss
lss
auctss
statist
signific
differ
ic
placebo
tabl
mean
durat
time
cold
equival
group
day
ic
day
placebo
patient
overal
assess
efficaci
similar
ic
placebo
ci
p
ic
placebo
frequent
patient
assess
good
ic
placebo
second
frequent
assess
fair
ic
placebo
tss
studi
day
day
mean
daili
tss
valu
highest
group
four
mandatori
treatment
day
tss
peak
day
placebo
group
wherea
tss
ic
group
decreas
steadili
without
reach
maximum
day
fig
tss
valu
lower
ic
group
placebo
group
day
mandatori
treatment
day
largest
differ
observ
day
treatment
day
tss
valu
lower
placebo
group
ic
group
unblind
three
previous
unplan
analys
perform
provid
better
understand
primari
endpoint
data
patient
tss
treat
ic
group
remov
exploratori
analysi
ontreat
symptom
score
well
rang
compar
adjust
mean
valu
placebo
ic
patient
tabl
suggest
patient
may
misunderstood
process
symptom
report
aberrantli
high
symptom
score
evid
entir
treatment
period
day
furthermor
respiratori
virus
detect
nasopharyng
sampl
exclud
data
patient
result
adjust
mean
tss
statist
significantli
lower
ic
group
tss
ex
pt
compar
placebo
group
p
tabl
ic
bind
virus
prevent
entri
cell
immedi
effect
symptom
score
could
also
reason
expect
addit
tss
placebo
group
increas
pretreat
baselin
day
indic
progress
cold
therefor
sensit
analysi
perform
use
mean
daili
tss
mandatori
treatment
day
tss
adjust
mean
tss
statist
signific
differ
favour
ic
p
tabl
final
order
adjust
baselin
sever
cold
tss
analys
rel
baselin
tss
rel
yield
statist
signific
differ
favour
ic
p
tabl
exploratori
analysi
subset
patient
test
posit
viru
baselin
yield
trend
favor
ic
averag
adjust
tss
score
point
lower
ic
group
compar
placebo
p
tabl
subset
patient
posit
rhinovirusenteroviru
baselin
averag
adjust
tss
valu
point
lower
placebo
p
tabl
includ
data
qualit
quantit
assay
proport
patient
test
posit
viru
baselin
patient
ic
group
patient
placebo
group
tabl
qualit
assay
frequent
virus
identifi
picornavirus
ic
fig
disposit
trial
patient
placebo
pbo
full
analysi
set
one
patient
extrem
outlier
tss
baselin
score
exclud
exploratori
analys
viru
posit
patient
posit
qualit
test
baselin
andor
detect
quantit
quantifi
nonquantifi
result
quantit
test
baselin
defin
detect
quantit
quantifi
nonquantifi
result
assay
quantifi
result
assay
patient
placebo
coronavirus
ic
placebo
tabl
baselin
day
virusposit
patient
ic
group
convert
virusneg
patient
placebo
group
convers
patient
ic
group
patient
placebo
group
virusneg
baselin
convert
virusposit
day
posthoc
analysi
quantit
data
viral
type
identifi
least
patient
treatment
group
baselin
analys
coronaviru
coronaviru
quantifi
assay
virus
quantifi
panenterhino
assay
substanti
reduct
viru
load
ic
group
compar
placebo
although
reach
statist
signific
tabl
coronavirus
decreas
mean
viru
quantiti
baselin
visit
similar
placebo
ic
group
reduct
greater
trial
seriou
ae
death
twelv
patient
report
ae
frequenc
similar
treatment
group
patient
ic
group
patient
placebo
group
ae
sever
intens
report
patient
ic
group
one
patient
headach
migrain
one
patient
toothach
one
patient
malais
patient
placebo
group
one
patient
headach
migrain
nausea
sore
throat
fatigu
one
patient
placebo
group
discontinu
treatment
due
ae
moder
epistaxi
patient
assess
toler
similar
treatment
group
major
rate
toler
nasal
spray
excel
good
good
ic
patient
placebo
patient
patient
ic
group
patient
placebo
group
assess
toler
treatment
poor
treatment
therefor
consid
safe
welltoler
random
doubleblind
placebocontrol
icicc
trial
conduct
evalu
safeti
efficaci
ic
treatment
patient
earli
common
cold
symptom
conduct
one
studi
site
primarili
among
univers
student
appar
good
health
except
earli
common
cold
symptom
analys
icicc
trial
support
find
three
previou
random
clinic
trial
examin
ic
nasal
spray
adult
children
acut
common
cold
symptom
adult
patient
administr
ic
nasal
spray
significantli
reduc
cold
symptom
viral
concentr
nasal
lavag
adult
patient
cold
durat
significantli
shorter
virusposit
patient
treat
ic
viral
load
significantli
reduc
significantli
faster
reduct
common
cold
symptom
first
day
treatment
children
although
signific
differ
ic
group
placebo
group
mean
total
symptom
score
exploratori
analys
indic
posit
effect
symptom
patient
less
comed
comed
use
icicc
trial
although
primari
endpoint
tss
demonstr
statist
signific
differ
ic
placebo
clear
trend
toward
benefit
ic
treatment
consist
trend
favor
ic
secondari
endpoint
statist
signific
outcom
exploratori
analys
also
observ
icicc
trial
find
nomin
greater
treatment
effect
seen
icicc
trial
among
patient
virusposit
support
pool
analysi
koenighof
combin
fazeka
ludwig
trial
pool
analysi
examin
patient
virusposit
show
nomin
respons
rate
higher
virusposit
patient
particip
ludwig
fazeka
trial
may
sever
reason
unexpectedli
low
power
trial
result
trend
rather
statist
signific
outcom
primari
endpoint
hrvhev
viral
load
reduct
first
proport
patient
respiratori
viru
could
detect
smaller
anticip
respiratori
virus
groupstyp
analys
found
baselin
patient
ic
group
placebo
group
effort
made
recruit
patient
earliest
onset
common
cold
thu
selfreport
cold
symptom
use
patient
inclus
criteria
without
requir
demonstr
viru
posit
enter
treatment
sinc
earli
symptom
common
cold
may
rather
nonspecif
respiratori
viru
infect
symptom
may
present
condit
vasomotor
rhiniti
certain
nonspecif
stimuli
includ
chang
environ
temperatur
humid
barometr
pressur
airborn
irrit
odor
fume
dietari
factor
spici
food
alcohol
emot
factor
trigger
nasal
symptom
patient
inadvert
includ
noninfecti
condit
would
expect
respond
clinic
antivir
therapi
therefor
like
caus
underestim
true
antivir
treatment
effect
consist
icicc
trial
demonstr
among
patient
quantifi
viru
baselin
ic
patient
greater
decreas
viral
load
placebo
patient
suggest
antivir
effect
ic
addit
tss
score
patient
virusposit
baselin
show
strong
trend
favor
ic
howev
sinc
subset
total
enrol
popul
virusposit
subset
underpow
tss
score
endpoint
particular
percentag
patient
hrvhev
identifi
baselin
substanti
smaller
anticip
quantifi
viru
ic
group
placebo
group
studi
use
molecular
method
viral
cultur
demonstr
human
rhinovirus
etiolog
agent
common
cold
current
trial
also
conduct
primarili
fall
octob
februari
includ
period
greatest
hrv
infect
incid
viru
shed
tend
greatest
first
sever
day
infect
gener
continu
week
unlik
low
posit
rate
hrvhev
infect
due
miss
window
hrv
shed
like
current
studi
conduct
season
low
hrv
preval
result
fewer
expect
infect
among
trial
patient
two
previou
clinic
trial
conduct
ic
number
patient
confirm
hrv
infect
higher
current
trial
although
valu
well
lower
percentag
report
studi
therefor
smallerthanexpect
number
patient
infect
hrvhev
virus
like
limit
icicc
trial
abil
differenti
ic
placebo
treatment
second
issu
affect
analysi
trial
inclus
one
patient
treat
ic
group
whose
tss
score
much
higher
expect
much
differ
trial
particip
patient
report
except
high
symptom
score
entir
treatment
period
day
auctss
higher
overal
popul
mean
valu
interestingli
viru
detect
patient
either
baselin
followup
sampl
readi
explan
aberr
valu
possibl
patient
misinterpret
symptom
score
methodolog
primari
endpoint
tss
reevalu
exclud
data
patient
differ
ic
placebo
patient
becam
statist
signific
two
exploratori
analys
support
conclus
ic
efficaci
ic
may
earli
effect
symptom
assess
ontreat
symptom
score
broaden
includ
day
comparison
tss
ic
placebo
group
demonstr
statist
signific
effect
ic
statist
signific
chang
tss
rel
baselin
two
addit
exploratori
analys
although
perform
small
sampl
reach
statist
signific
also
support
assert
ic
efficaci
tss
score
pcrconfirm
respiratori
virusposit
patient
averag
point
lower
ic
group
compar
placebo
tss
score
patient
pcrconfirm
rhinoviru
infect
also
averag
point
lower
ic
group
daybyday
tss
score
indic
advantag
ic
day
appear
lost
day
clear
appar
tss
advantag
disappear
later
treatment
day
howev
placebo
salin
nasal
spray
may
ic
spray
regist
market
medic
devic
sever
european
countri
intend
use
patient
earli
cold
symptom
data
sever
experi
suggest
mechan
action
may
prevent
bind
attach
site
andor
interfer
viral
entri
first
vitro
studi
demonstr
activ
varieti
virus
variou
strain
hrv
influenza
herpesviru
dengueviru
papillomaviru
nonspecif
suggest
absenc
specif
directact
antivir
daa
secondli
observ
antivir
effect
occur
earli
infect
cycl
like
stage
attach
andor
entri
antivir
effect
tend
ic
concentrationdepend
therefor
unlik
carrageenan
effect
daa
target
metabol
reproduct
mechan
sinc
varieti
virus
caus
common
cold
sinc
viru
infect
cycl
typic
involv
bind
entri
nasal
mucos
cell
antivir
properti
iota
carrageenan
repres
attract
promis
option
treatment
publish
clinic
evid
concern
frequenc
detect
virus
vari
modern
techniqu
virus
particularli
rhinovirus
found
patient
suffer
cold
symptom
therefor
expect
reallif
condit
patientsconsum
empir
choos
use
ic
spray
rel
high
likelihood
infect
rhinoviru
one
varieti
respiratori
virus
manifest
common
cold
symptom
uncertainti
true
infect
set
counterbalanc
low
intoler
toxic
rate
ic
spray
rel
inexpens
thu
give
favor
potenti
benefitrisk
benefitcost
ratio
empir
use
ic
spray
clinic
trial
cough
cold
substanti
proport
studi
demonstr
trend
may
reach
statist
signific
efficaci
outcom
observ
may
due
larg
variabl
diseas
sever
nativ
infect
patient
recruit
earli
stage
cold
control
clinic
trial
tri
recruit
patient
earliest
stage
common
cold
symptom
still
emerg
mild
patient
may
incorrectli
believ
come
cold
prior
full
blown
cold
symptom
rel
low
frequenc
rhinovirusposit
patient
icicc
studi
demonstr
often
tradeoff
standard
design
use
cold
studi
peculiar
outcom
icicc
studi
also
use
may
trigger
discuss
among
scientif
commun
suitabl
studi
design
investig
common
cold
treatment
furthermor
result
icicc
studi
line
mani
common
cold
studi
show
rel
small
effect
treatment
symptom
sever
durat
one
exampl
studi
barrett
et
al
echinacea
show
well
trend
direct
benefit
amount
averag
half
day
reduct
durat
weeklong
cold
approxim
reduct
overal
sever
author
conclud
result
allow
us
reject
null
hypothesi
confid
claim
evidenceofbenefit
data
also
insuffici
exclud
possibl
clinic
signific
effect
although
address
icicc
trial
ic
antivir
properti
lead
specul
use
might
decreas
cold
transmiss
patient
famili
member
social
contact
although
icicc
studi
fail
reach
statist
signific
outcom
primari
secondari
endpoint
strong
trend
favour
treatment
effect
ic
observ
primari
secondari
endpoint
consist
tend
improv
ic
spray
group
compar
placebo
group
clinic
relev
effect
size
even
though
popul
includ
patient
low
baselin
score
sever
ration
import
exploratori
analys
led
statist
signific
clinic
relev
outcom
differ
unfortun
rel
low
number
subject
demonstr
viral
infect
limit
studi
conclus
nonetheless
outcom
icicc
studi
support
previou
evid
ic
vitro
antivir
activ
symptom
viral
reduct
prior
cold
studi
icicc
trial
outcom
support
ic
spray
repres
potenti
use
treatment
option
common
cold
trial
result
show
safe
welltoler
minim
invas
well
suggest
efficaci
